293 related articles for article (PubMed ID: 36472553)
1. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Kemp SB; Cheng N; Markosyan N; Sor R; Kim IK; Hallin J; Shoush J; Quinones L; Brown NV; Bassett JB; Joshi N; Yuan S; Smith M; Vostrejs WP; Perez-Vale KZ; Kahn B; Mo F; Donahue TR; Radu CG; Clendenin C; Christensen JG; Vonderheide RH; Stanger BZ
Cancer Discov; 2023 Feb; 13(2):298-311. PubMed ID: 36472553
[TBL] [Abstract][Full Text] [Related]
2. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
Wei D; Wang L; Zuo X; Maitra A; Bresalier RS
Clin Cancer Res; 2024 Feb; 30(4):655-662. PubMed ID: 37831007
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma.
Gulay KCM; Zhang X; Pantazopoulou V; Patel J; Esparza E; Pran Babu DS; Ogawa S; Weitz J; Ng I; Mose ES; Pu M; Engle DD; Lowy AM; Tiriac H
Cancer Res; 2023 Sep; 83(18):3001-3012. PubMed ID: 37378556
[TBL] [Abstract][Full Text] [Related]
4. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
[TBL] [Abstract][Full Text] [Related]
5. Precise and efficient silencing of mutant Kras
Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
[No Abstract] [Full Text] [Related]
6. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
7. KRAS
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Paradiso F; Sugimoto H; Arian KA; Ying H; Barekatain Y; Sthanam LK; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
Cancer Cell; 2023 Sep; 41(9):1606-1620.e8. PubMed ID: 37625401
[TBL] [Abstract][Full Text] [Related]
8. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
[TBL] [Abstract][Full Text] [Related]
9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
10. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
11. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
12. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
13. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
14. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
[TBL] [Abstract][Full Text] [Related]
15. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.
Bianchi A; De Castro Silva I; Deshpande NU; Singh S; Mehra S; Garrido VT; Guo X; Nivelo LA; Kolonias DS; Saigh SJ; Wieder E; Rafie CI; Dosch AR; Zhou Z; Umland O; Amirian H; Ogobuiro IC; Zhang J; Ban Y; Shiau C; Nagathihalli NS; Montgomery EA; Hwang WL; Brambilla R; Komanduri K; Villarino AV; Toska E; Stanger BZ; Gabrilovich DI; Merchant NB; Datta J
Cancer Discov; 2023 Jun; 13(6):1428-1453. PubMed ID: 36946782
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. Atypical KRAS
Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
[TBL] [Abstract][Full Text] [Related]
18. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.
Garcia MN; Grasso D; Lopez-Millan MB; Hamidi T; Loncle C; Tomasini R; Lomberk G; Porteu F; Urrutia R; Iovanna JL
J Clin Invest; 2014 Nov; 124(11):4709-22. PubMed ID: 25250570
[TBL] [Abstract][Full Text] [Related]
19. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
20. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA; Han JJW; Lee YH; Lee CS; Luo J
Cancer Res; 2023 Sep; 83(17):2816-2823. PubMed ID: 37339170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]